Clinical trials
Wet Age-related Macular Degeneration clinical trials
Below are recruiting wet age-related macular degeneration clinical trials, each written for real people, not researchers. We’re tracking 32 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05445063RecruitingPhase 1
iPSC eye-cell transplant for late dry macular degeneration
This Phase 1 study tests an experimental transplant made from your own cells to try to improve vision in people with advanced “late dry” age-related macular degeneration (AMD). It focuses first on safety, and may help some participants with limited central vision.
Beijing, Beijing MunicipalityAges 50–75 - NCT02253030Recruiting
Eye scan study for newly diagnosed wet AMD
This study uses a special eye scan (OCT angiography) to look at new, abnormal blood vessel growth in people with wet age-related macular degeneration (wet AMD) who have not been treated yet. It may help researchers better understand the disease and how it changes over time.
Portland, OregonAges 50–100 - NCT06492863RecruitingPhase 1/Phase 2
Gene therapy (FT-003) for wet AMD
This trial tests a new gene therapy, FT-003, for people with wet AMD. It aims to see if a single treatment can help stop vision loss and may reduce the need for frequent eye injections.
Tianjin, Tianjin,ChinaAges 50–80 - NCT07798323Recruiting
Imaging study for dry age-related macular degeneration
This study uses special eye scans and tests to look for blood vessel problems that may be linked to dry age-related macular degeneration (AMD). It might help find new ways to treat the condition.
Cleveland, OhioAges 50–80 - NCT07776522RecruitingPhase 2
Gene therapy for wet age-related macular degeneration
This trial tests a one-time gene therapy injection under the retina for people with wet age-related macular degeneration (AMD), which causes blurry vision from abnormal blood vessels. It aims to reduce the need for frequent eye injections by delivering a treatment that may help the eye produce its own medicine.
Beijing, Beijing MunicipalityAges 50–85 - NCT07770828RecruitingPhase 3
Gene therapy for advanced dry age-related macular degeneration
This trial tests an experimental gene therapy, OCU410, for people with geographic atrophy, an advanced form of dry AMD that causes blind spots in the center of vision. The study aims to see if this treatment can slow down the progression of the disease and help preserve remaining vision.
Phoenix, ArizonaAges 55 years+ - NCT07695207RecruitingPhase 3
Testing SMZ1 with ranibizumab for wet macular degeneration
This trial tests a new medicine called SMZ1 combined with ranibizumab (a standard treatment) for people with wet macular degeneration. It may help improve vision by targeting the cause of the disease more effectively.
Seoul, SeoulAges 50 years+ - NCT07630649RecruitingPhase 2
Gene therapy for wet age-related macular degeneration in second eye
This study tests a one-time gene therapy injection (ixoberogene soroparvovec) in the second eye of people with wet age-related macular degeneration who have already responded well to anti-VEGF injections. The goal is to see if this gene therapy can help preserve or improve vision in that eye.
Phoenix, ArizonaAges 50 years+ - NCT02669953Recruiting
Aflibercept injections for persistent wet macular degeneration
This trial studies whether aflibercept injections can help when “wet” age-related macular degeneration is recurring or not fully going away. It focuses on adults who have already had ranibizumab and still have measurable vision in the study eye.
ViennaAges 50 years+ - NCT06718816Recruiting
Long-term follow-up of AL-001 eye injection for wet AMD
This trial is a long-term follow-up for people who already received the AL-001 eye injection for wet age-related macular degeneration (wet AMD) in an earlier study. It will check how you are doing over time.
Beijing, Beijing MunicipalityAges 50 years+ - NCT07587515RecruitingPhase 1/Phase 2
New Eye Drop Treatment for Wet Age-Related Macular Degeneration
This study tests a new experimental eye drop (EYC-0305) for wet AMD, a common cause of vision loss in older adults. The goal is to see if it can slow or prevent further damage to central vision.
Beverly Hills, CaliforniaAges 50 years+ - NCT07496567RecruitingPhase 2/Phase 3
Study of EYE201 for wet age-related macular degeneration
This trial tests a new medicine, EYE201, for people with wet age-related macular degeneration (AMD) that has not been treated before. The study will see if this drug can help improve vision and slow down vision loss.
Gilbert, ArizonaAges 50 years+ - NCT07482176RecruitingPhase 3
Gene therapy trial for wet age-related macular degeneration
This trial tests a one-time gene therapy injection (IXO-vec) for people with wet age-related macular degeneration (nAMD). It aims to reduce the need for frequent eye injections by helping the eye make its own medicine to block the growth of harmful blood vessels.
Mesa, ArizonaAges 50 years+ - NCT07440225RecruitingPhase 2/Phase 3
Testing a new drug for wet macular degeneration
This trial tests a new medicine called EYE201/MK-8748 for people who have wet age-related macular degeneration (a condition where abnormal blood vessels grow under the retina). It's for those who haven't had treatment before and were diagnosed recently.
Scottsdale, ArizonaAges 50 years+ - NCT06132035RecruitingPhase 1
CG-P5 eye drops for wet macular degeneration
This study tests a new eye drop (CG-P5) for people with wet age-related macular degeneration. It aims to see if the drops are safe and may help improve vision.
Manchester, ConnecticutAges 50 years+ - NCT07392255RecruitingPhase 1/Phase 2
Testing CTx001 for geographic atrophy (GA) in AMD
This trial is testing a new treatment called CTx001 for people with geographic atrophy (GA), a late stage of dry age-related macular degeneration (AMD). The goal is to see if the treatment is safe and can slow vision loss.
Carmel, IndianaAges 55 years+ - NCT07338513Enrolling by invitation
Home eye-tracking tool for wet AMD monitoring
This study tests a web-based eye-tracking tool to monitor vision impairment in people with wet age-related macular degeneration (AMD). You would use your computer at home, which could help reduce the need for frequent clinic visits.
SingaporeAges 55–99 - NCT07317934RecruitingPhase 3
Gene therapy for wet age-related macular degeneration
This study tests a one-time gene therapy called LX102 for wet age-related macular degeneration (AMD). It may reduce the need for frequent eye injections and help preserve vision.
Hefei, AnhuiAges 50–80 - NCT06875245RecruitingPhase 4
Comparing 8-Week vs 12-Week Faricimab for Wet AMD
This trial compares two different schedules (8 weeks vs 12 weeks) for follow-up injections of faricimab in people who are starting treatment for wet AMD. It aims to see if a longer gap between doses works just as well as the shorter interval.
PragueAges Any age - NCT07185841RecruitingPhase 1/Phase 2
Oral tablets for wet macular degeneration
This trial tests an experimental oral tablet for people with wet age-related macular degeneration. It may offer a new way to treat the condition without frequent eye injections.
BeijingAges 50–85 - NCT07144137Recruiting
Observation study for geographic atrophy progression
This study observes how geographic atrophy (an advanced form of dry age-related macular degeneration) changes over a short period. If you have this condition in both eyes and meet certain vision and eye health criteria, you may be able to join this non-treatment study to help researchers learn more about the disease.
Mountain View, CaliforniaAges 55 years+ - NCT06952452RecruitingPhase 3
Testing genes to improve AMD treatment
This trial studies how genes affect response to anti-VEGF injections for a common form of age-related vision loss (wet AMD). It aims to tailor treatment to each patient.
San Cristóbal de La Laguna, Santa Cruz De TenerifeAges 50 years+ - NCT06859515Recruiting
Long-term follow-up for wet AMD treatment
This study checks on the long-term safety and effects of a one-time treatment (EXG102-031) for wet age-related macular degeneration. It is only for people who already received that treatment in a previous study.
BeijingAges 50 years+ - NCT06659445RecruitingPhase 2
Study of ONL1204 for geographic atrophy in dry AMD
This study tests an investigational medicine called ONL1204 given as an injection into the eye for people with a form of advanced dry age-related macular degeneration called geographic atrophy. The goal is to see if it can slow vision loss.
Gilbert, ArizonaAges 55 years+
Hear when a new Wet Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Wet Age-related Macular Degeneration trials by city
Studies with a site in or near these metro areas.
Wet Age-related Macular Degeneration trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for wet age-related macular degeneration?
- Yes. Clin2 currently lists 32 recruiting wet age-related macular degeneration studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a wet age-related macular degeneration trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a wet age-related macular degeneration trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Neovascular (Wet) Age-Related Macular Degeneration
- Wet Age-related Macular Degeneration (wAMD)
- Age-Related Macular Degeneration
- Neovascular Age-related Macular Degeneration
- Neovascular Age-Related Macular Degeneration (nAMD)
- Dry Age-related Macular Degeneration
- Age-related Macular Degeneration (ARMD)
- Exudative Age-Related Macular Degeneration
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.